ICH plan to reduce rat carcinogenicity studies moves into new phase
This article was originally published in Scrip
International plans to reduce the need for the two-year rodent carcinogenicity test, and thereby possibly reduce drug development timelines and increase speed to market, are among the issues to be discussed at the International Conference on Harmonization (ICH) meeting next month in Osaka, Japan.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.